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Background: Perioperative chemotherapy plus surgery is one recommended standard
treatment for patients with resectable gastric and esophageal cancer. Even with a
multimodality treatment more than half of patients will relapse following surgical resection.
Patients who have a poor response to neoadjuvant chemotherapy and have an
incomplete (R1) resection or have metastatic lymph nodes in the resection specimen
(N+) are especially at risk of recurrence. Current clinical practice is to continue with the
same chemotherapy in the adjuvant setting as before surgery. In the phase II randomized
EORTC VESTIGE trial (NCT03443856), patients with high risk resected gastric or
esophageal adenocarcinoma will be randomized to either adjuvant chemotherapy (as
before surgery) or to immunotherapy with nivolumab and low dose ipilimumab (nivolumab
3 mg/kg IV Q2W plus Ipilimumab 1 mg/kg IV Q6W for 1 year). The primary endpoint of
the study is disease free survival, with secondary endpoints of overall survival, safety
and toxicity, and quality of life. This is an open label randomized controlled multi-center
phase-2 superiority trial. Patients will be randomized in a 1:1 ratio to study arms. The
trial will recruit 240 patients; recruitment commenced July 2019 and is anticipated to
take 30 months. Detailed inclusion/exclusion criteria, toxicity management guidelines,
and statistical plans for EORTC VESTIGE are described in the manuscript.
Clinical Trial Registration: The trial is registered with www.ClinicalTrials.gov, identifier:
NCT03443856.
Keywords: gastric cancer, gastroesophageal cancer, immunotherapy, chemotherapy, adjuvant, nivolumab,
ipilimumab, perioperative
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INTRODUCTION
Background and Rationale
Gastric and esophageal cancer are amongst the most prevalent
cancers globally; gastric cancer was diagnosed in 1,033,701
patients worldwide in 2018, whereas esophageal cancer occurred
in 572,034 cases globally (1). Both gastric cancer and esophageal
adenocarcinomas are associated with poor survival for patients
with metastatic disease. Median survival is <1 year, and even
for patients with resectable cancers who are treated with
optimum multimodality treatment and surgery, long term
survival is <50% (2–4). Perioperative chemotherapy is one
standard of care in Europe for treatment of AJCC 8th edition
clinical stage Ib—IVa (resectable) gastric and esophagogastric
junction (EGJ) adenocarcinoma, according to the current
European Society for Medical Oncology (ESMO) clinical
practice guidelines; in non-Asian countries for esophageal
and junctional adenocarcinoma chemoradiotherapy may also
be considered whereas in Asia, adjuvant chemotherapy is
preferred for gastric cancers (5, 6). Compared with resection
alone, this treatment has increased survival rates by about
up to 15% after 5 years of follow-up (7, 8). Appropriate
chemotherapy regimens include platinum (either oxaliplatin
or cisplatin) and fluoropyrimidine doublets or triplet
chemotherapy. Since 2017, the FLOT regimen (docetaxel,
oxaliplatin, fluorouracil, and leucovorin) has been considered
the treatment of choice for patients who are fit for three drug
combinations (4).
Negative Prognostic Features in Patients
Treated With Perioperative Chemotherapy
and Surgery
In the MAGIC randomized control trial which defined
perioperative ECX (epirubicin, cisplatin, and capecitabine)
chemotherapy as a standard of care, patients who did not achieve
a good pathological response to preoperative chemotherapy
and who present with a positive nodal status (ypN+) or
with an R1 resection status after preoperative chemotherapy
have a very poor prognosis (9, 10). In this study the median
survival of patients with node positive resected cancer (ypN1-
3) was only 16 months and the 5-year survival rate was
only 20%. It is notable that most recurrences occur early,
within the first 2 years of follow-up. The prognosis of good
responders to preoperative chemotherapy, who have a negative
nodal status and undergo R0 resection, in contrast, is better.
The median overall survival for all node-negative patients
(regardless of the pathological tumor regression status) was not
reached because it was greater than the longest censoring time.
The 5-year survival rate was 66 and 71% for nodal-negative
responders and non-responders; negative nodal status being
the only independent positive prognostic factor in multivariate
analysis (5).
Currently, patients who have a poor response to
chemotherapy (due to remaining positive lymph nodes
or a R1 resection) continue with the same treatment
postoperatively as they did preoperatively as all the trials
which defined these treatment approaches used pre and
post-operative chemotherapy. However, within the oncology
community there is a desire for better treatments rather
than continuing with the same treatment which has been
less effective than is desirable before surgery. Considering
the known toxicities of classical chemotherapy regimens,
a “switch” to a different treatment is attractive for high
risk postoperative patients, but this should be assessed
in the context of a randomization against the current
recommended standard treatment which is postoperative
adjuvant chemotherapy similar to that which the patient received
before surgery.
Although survival for patients who have node positive
disease after surgery in the FLOT4/AIO trial has not been
presented, 51% of patients treated with FLOT were node
positive (N+) after surgery, and 16% of patients had an
R1 resection. Therefore, the proportion of patients who are
high risk for recurrence after surgery is still high even in
patients in whom FLOT is adopted as a standard of care
(4). In general, therefore considering the activity of currently
available chemotherapy regimens, the group of high risk
non-chemoresponsive patients constitutes ∼2/3 of those who
undergo neoadjuvant chemotherapy. This relatively large group
of patients has clear need for improved outcomes and better
postoperative treatment.
Immunotherapy for Gastric and
Esophageal Adenocarcinoma: Rationale
for PD-1 Inhibition
Immunotherapy in the form of checkpoint inhibition has shown
efficacy in the treatment of patients with advanced gastric
and esophagogastric junction (EGJ) cancers. Nivolumab is a
humanized monoclonal, immunoglobulin G4 antibody directed
against PD-1 which is licensed to treat melanoma, non-small
cell lung cancer (NSCLC) and other cancers including small cell
lung cancer, renal cell carcinoma, classical Hodgkin lymphoma,
squamous cell carcinoma of the head and neck, urothelial cancer,
MSI-H or dMMRmetastatic colorectal cancer, and hepatocellular
cancer (11–13).
Recently, nivolumab has received approval for advanced
gastric cancer in Japan. In the ONO-4538-12 (ATTRACTION-2)
trial, a phase III randomized study, patients with chemorefractory
unresectable advanced or recurrent gastroesophageal cancer were
randomized to either nivolumab 3 mg/kg every 2 weeks or
placebo (14). The primary endpoint of the trial was overall
survival, with secondary endpoints of progression free survival,
best overall response and safety. A total of 493 patients were
recruited and randomized in a 2:1 ratio to receive nivolumab
or placebo. Treatment with nivolumab significantly improved
median overall survival from 4.14 to 5.32 months [HR 0.63;
95% CI (0.50–0.78), p < 0.0001]. Survival at 12 months was
almost doubled for nivolumab treated patients; this being
26.6% for nivolumab and 10.9% for patients treated with
placebo. In nivolumab treated patients, RECIST responses were
observed in 12% of patients, however some tumor shrinkage was
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observed in 40% of patients. A survival benefit for nivolumab
treatment was observed for patients with and without PD-
L1 expression (PD-L1 negative median OS 6.1 vs. 4.2 months
nivolumab vs. placebo; PD-L1 positive median OS 5.2 vs. 3.8
months nivolumab vs. placebo) (15). Therefore, nivolumab
is effective in chemorefractory gastric cancer regardless of
PD-L1 status. Results like those observed in Asian patients
with single agent nivolumab in ATTRACTION-2 have been
demonstrated also in non-Asian patients in the CHECKMATE-
032 study (16).
Similar results to nivolumab in gastric and gastroesophageal
cancer have been demonstrated for pembrolizumab, which
is a humanized immunoglobulin G4 monoclonal antibody
targeting PD-1 which is licensed to treat melanoma, NSCLC
and microsatellite unstable cancers of any tumor site (17–
19). In the KEYNOTE 059 study cohort 1, 259 patients
who had previously been treated with two or more lines
of chemotherapy received pembrolizumab 200mg Q3W
(20). Approximately half (52%) of patients had tumors of
the gastroesophageal junction. In KEYNOTE-059 cohort 1
radiological responses were observed in 12% of all patients (with
a higher response rate in PD-L1 positive tumors [combined
proportion score of ≥1] of 15%) and 42% of patients had
some evidence of tumor shrinkage. These results are very
consistent with those observed for single agent nivolumab,
indicating a class effect of anti-PD-1 therapy in gastric and
gastroesophageal cancer.
Rationale for Combination CTLA4 and
PD-1 Inhibition
Metastatic melanoma treated with combination anti-cytotoxic
T lymphocyte associated protein 4 (CTLA4) and PD-1
therapy leads to increased response rates and progression
free survival compared to single agent immunotherapy in
particular for PD-L1 negative patients (12, 21–25). As most
patients with gastroesophageal cancer have PD-L1 negative
tumors, combination immune checkpoint blockade may be
helpful in this disease. In two of the three of the Phase I/II
CHECKMATE 032 study arms, nivolumab and ipilimumab
were assessed at two dose levels; these were nivolumab 3 mg/kg
plus ipilimumab 1 mg/kg Q3W (N3 plus I1) or nivolumab
1 mg/kg plus ipilimumab 3 mg/kg Q3W (N1 plus 13) (16).
Landmark eighteen-month survival was 28% for N1 plus I3
patients and 13% for N3 plus I1 patients and radiological
response rates were also increased for combination therapy,
in particular for PD-L1 negative patients. Therefore, in a
subsequent ongoing randomized trial in first-line stage IV
gastric cancer, the N1 plus I3 regimen was selected for further
investigation. However, this combination was found to result
in excessive toxicity and a reduced dose of ipilimumab has
been recommended as an alternative regimen depending on
the setting.
Most recently, data on the safety and efficacy of dosing
nivolumab at 3 mg/kg Q2W + 1 mg/kg Q6W dosing of
ipilimumab has emerged from several trials (26). This dose
was optimized across 8 cohorts of NSCLC in the Checkmate
012 study and then evaluated prospectively in the randomized
Checkmate 227 study (27). In Checkmate 227 toxicity for
the combination of nivolumab with low dose ipilimumab
was similar compared with chemotherapy with respect to
grade 3–4 treatment related adverse events. For example, the
proportion requiring systemic corticosteroid use for immune
related toxicity for each of the following organ systems was
14% (dermatological), 17% (endocrine), 36% (gastrointestinal),
44% (hepatic), 23% (renal), most of which resolved with
steroid treatment. The combination of nivolumab 3 mg/kg
Q2W and ipilimumab 1 mg/kg Q6W has now been evaluated
in 941 patients across 3 trials (Checkmate 012, 227, and
568 studies) and found to have manageable toxicity with a
low incidence of treatment-related adverse events leading to
treatment discontinuation of between 12 and 17.4% in these
studies. This represents a significant improvement on prior
dosing schedules and therefore this regimen has been adopted for
the VESTIGE trial.
VESTIGE STUDY OBJECTIVES
Primary Objective
The primary objective of the trial is to investigate if nivolumab
plus ipilimumab given as adjuvant treatment improve disease
free survival (DFS) in patients with AJCC 8th edition stage Ib-
IVa gastric and esophagogastric (EG) junctional adenocarcinoma
and high risk of recurrence (defined by ypN1-3 and/or R1 status)
following neoadjuvant chemotherapy and resection.
Secondary Study Objectives
To investigate the safety and effect of adjuvant immunotherapy
on long term oncologic outcomes and quality of life of patients in
the study.
To correlate nutritional status assessment with outcomes and
quality of life of patients.
Trial Design
This is an open label randomized controlled multi-center phase-
2 superiority trial. Patients will be randomized in a 1:1 ratio to
study arms.
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Study Setting
The study will be conducted at EORTC study sites which
may include academic and non-academic hospitals and cancer
centers. The trial will be conducted in the following countries
(Czech Republic, France, Germany, Israel, Italy, Norway, Poland,
Portugal, Spain, United Kingdom). A list of sites can be found
on clinicaltrials.gov.
Eligibility Criteria
Inclusion Criteria
• Histologically proven gastric, lower esophageal or EG-junction
adenocarcinoma (Siewert I-III).
• Subjects must have completed pre-operative chemotherapy
with a fluoropyrimidine-platinum containing
regimen and macroscopically complete surgery
prior to randomization.
• Minimal duration of neoadjuvant chemotherapy should be 6
weeks, maximum 12 weeks.
• Total or distal gastrectomy with D2 lymphadenectomy
according to ESMO guidelines should have been
completed for gastric and EG junctional Siewert
type III cancers.
• Ivor Lewis or McKeown esophagectomy with two
field lymphadenectomy should have been performed
for EG junctional Siewert type I cancers and lower
esophageal adenocarcinomas.
• For Siewert type II cancers either total gastrectomy with
D2-lymphadenectomy or esophagectomy with two field
lymphadenectomy should have been completed.
• Open, minimal invasive or hybrid surgical approaches are
acceptable as long as the requirements above are fulfilled.
• Regardless of the type of surgery a minimum of 15 lymph
nodes should have been resected and examined.
• Recovered from surgery and fit for study treatment as assessed
by a multidisciplinary team.
• Ideally, surgery should have been completed no longer than 2
months before randomization.
• ypN1-3 status according to current (8th) version of TNM
classification system. In case of an ypN0 status patients must
meet the inclusion criterion of R1 resection.
• R0 or R1 resection according to current (8th) version of TNM
classification system. In case of R0 resection, patients must
meet the inclusion criterion of ypN1-3.
• WHO performance status score of 0 or 1.
• Age ≥ 18 year.
• Adequate organ function assessed within 7 days
before randomization:
◦ White blood cell count (WBC) > 2× 109/L.
◦ Absolute neutrophil count (ANC) > 1.5× 109/L.
◦ Platelets≥ 100× 109/L.
◦ Hemoglobin ≥ 9 g/Dl.
◦ Measured/calculated creatinine clearance ≥ 60 mL/min
(according to Cockroft-Gault formula).
◦ Total bilirubin within normal limits (if the patient has
documented Gilbert’s disease ≤ 1.5 ∗ ULN or direct
bilirubin ≤ ULN).
◦ Aspartate transaminase (AST) and alanine transaminase
(ALT) ≤ 1.5ULN.
• Normal 12-lead ECG, and if clinically indicated, normal
cardiac function assessment (using either echocardiography or
MUGA Scan).
• In the past 6 months no serious cardiac illness or medical
condition including but not confined to:
◦ History of documented congestive heart failure (CHF).
◦ High-risk uncontrolled arrhythmias.
◦ Angina pectoris requiring antianginal medication.
◦ Clinically significant valvular heart disease.
◦ Evidence of transmural infarction.
◦ Poorly controlled hypertension (e.g., systolic >180mm Hg
or diastolic >100mm Hg).
• All toxicities (exception alopecia, and grade 2 fatigue,
neuropathy, and lack of appetite /nausea) attributed to prior
anti-cancer therapy must have resolved to grade 1 (NCI
CTCAE version 5.0 or baseline before administration of
study drug.
• Availability of resected tumor for biobanking/TR.
• Women of childbearing potential (WOCBP∗) must have a
negative serum or urine pregnancy test [minimum sensitivity
25 IU/L or equivalent units of human chorionic gonadotropin
(HCG)] within 24 h prior to randomization.
• WOCBP should use highly effective method of birth
control measures during the study treatment period
and for at least 6 months after the last dose of the
study treatment.
• Female subjects who are breast feeding should
discontinue nursing prior to the first dose of study
treatment and until 6 months after the last dose of the
study treatment.
• Men who are sexually active with an WOCBP must adhere to
contraception for a period of 7 months after the last dose of the
study treatment.
• Absence of any psychological, familial, sociological, or
geographical condition potentially hampering compliance
with the study protocol and follow-up schedule; those
conditions should be discussed with the patient before
registration in the trial.
• Before patient registration/randomization, written informed
consent must be given according to ICH/GCP, and
national/local regulations.
Exclusion Criteria
• R2 Resection Status.
• M1 stage according to the current (8th) version of TNM
classification system.
• Patients who have undergone complete resection
of metastases.
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• Impaired renal, hepatic, cardiac, pulmonary, or endocrine
status that compromises the eligibility of the patient for
postoperative chemotherapy or immunotherapy.
• Subjects with previous malignancies are excluded unless a
complete remission was achieved at least 5 years prior to
study entry.
◦ Adequately treated cervical carcinoma in situ, and localized
non-melanoma skin cancer are no exclusion criteria,
regardless of timepoint of diagnosis.
• Subjects with active, known, or suspected infectious or
autoimmune disease.
• Patients who have received antibiotics within the last 14 days
before randomization are excluded.
• Subjects with Type I diabetes mellitus, residual
hypothyroidism due to autoimmune thyroiditis only
requiring hormone replacement, skin disorders (such
as vitiligo, psoriasis, or alopecia) not requiring systemic
treatment are permitted to enroll.
• Subjects with a condition requiring systemic treatment
with either corticosteroids (≥ 10mg daily prednisone or
equivalent) or other immunosuppressive medications within
14 days of study drug administration.
• Subjects with interstitial lung disease who have clinical
findings that may interfere with the detection or management
of suspected drug-related pulmonary toxicity from the study.
• Subjects with > Grade 1 peripheral neuropathy.
• Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2,
anti-CD137, or anti-CTLA-4 antibody, or any other antibody
or drug specifically targeting T-cell co-stimulation or immune
checkpoint pathways.
• Prior or concomitant treatment with radiotherapy/
radiochemotherapy.
• Any positive test result for HBV or HCV indicating acute or
chronic infection.
• Known history of testing positive for HIV or known AIDS.
• Known uncontrollable hypersensitivity to the
components or excipients of nivolumab, ipilimumab,
cisplatin/oxaliplatin, 5-FU or capecitabine, epirubicin
or docetaxel.
• Known dihydropyrimidine dehydrogenase (DPD) deficiency.
• Ongoing or concomitant use of the antiviral drug
sorivudine or its chemically related analogs, such
as brivudine.
Excluded Medications
The following medications are not permitted during the study
(unless used to treat a drug related adverse event):
• Immunosuppressive drugs.
• Immunosuppressive doses of systemic corticosteroids (except
for controlling immune related adverse events).
• Any other anti-cancer therapy (i.e., chemotherapy, hormonal
therapy, immunotherapy, radiotherapy).
• Live vaccines < 4 weeks prior to and during study treatment
are prohibited therapies. Examples of live vaccines include,
but are not limited to, the following: measles, mumps,
rubella, chicken pox, yellow fever, H1N1 flu, rabies, BCG, and
typhoid vaccine.
The following medications should be avoided with capecitabine:
• Warfarin: patients receiving capecitabine and warfarin will
require more frequent INR monitoring.
• Phenytoin: blood phenytoin levels can increase
with capecitabine.
• Folic acid: multivitamin supplements containing folic
acid should be avoided as it could potentially increase
capecitabine toxicity.
• Allopurinol: potentially reduces the effectiveness
of capecitabine.
• Interferon α: reduces maximal tolerated dose of capecitabine.
Interventions
Experimental Arm
Total treatment time 1 year. No adjuvant chemotherapy.
Treatment: nivolumab 3 mg/kg IV Q2W plus ipilimumab 1
mg/kg IV Q6W for 1 year.
Control Arm
Completion of the same perioperative treatment according to the
2016 ESMO guidelines (change of regimen is not allowed).
Perioperative Chemotherapy May Include
∗Physiciansmay useminormodifications of these regimens if this
is judged acceptable by the local investigator.
Cisplatin + Fluorouracil (CF)
Fluouracil 800 mg/m2 IV continuous infusion over 24 h daily on
Days 1–5; Cisplatin 75–80 mg/m2 IV on day 1; cycled every 28
days for 2–3 cycles preop and 3–4 cycles postop for a total of
6 cycles.
Cisplatin + Capecitabine (CX)
Cisplatin (80 mg/m2 every 3 weeks) and capecitabine (1,000
mg/m2 twice daily every 2 out of 3 weeks) for three cycles.
Epirubicin + Cisplatin + Fluorouracil (ECF)
Epirubicin 50 mg/m2 intravenously day 1, cisplatin 60 mg/m2
intravenously day 1, and 5-fluorouracil 200 mg/ m2/day
intravenously continuous infusion over 24 h daily on days 1–21.
Cycle is every 21 days for 3 cycles preop and post op.
Epirubicin + Cisplatin + Capecitabine (ECX)
Epirubicin 50 mg/m2 intravenously day 1, cisplatin 60 mg/m2
intravenously day 1, and capecitabine 625 mg/m2 twice daily
on days 1–21. Cycled every 21 days for 3 cycles preop and 3
cycles postop.
Epirubicin + Oxaliplatin + Capectabine (EOX)
Epirubicin 50 mg/m2 IV on day 1, oxaliplatin 130 mg/m2 IV on
day 1 with hydration, capecitabine 1,250 mg/m2/day PO in two
divided doses continuously from days 1–21. Cycled every 21 days
for 3 cycles preop and 3 cycles postop.
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Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX)
Day 1: oxaliplatin 85 mg/m2 IV infusion, 400 mg/m2 leucovorin
IV infusion, followed by 5-FU 400 mg/m2 IV push then 5-FU
1,200 mg/m2 IV infusion for 22 h; day 2: 5-FU 1,200 mg/m2 IV
infusion for 24 h daily on Days 1 and 2. Cycled every 14 days for
4 cycles. mFOLFOX6 is administered in cycles of 2 weeks for 4
cycles (= 8 weeks) on day 1, 15, 29 and 43. Oxaliplatin is given
as a 2 h intravenous infusion at a dose of 85 mg/m2. Oxaliplatin
needs to be diluted with 250–500ml of 5% glucose solution and
followed by leucovorin 400 mg/m2 iv over 2 h on day 1, and 5-
FU 400 mg/m2 iv bolus on day 1, then 2,400 mg/m2 over 46–48 h
continuous infusion.
Capecitabine + Oxaliplatin (CapeOx)
CapeOx is administered in cycles of 3 weeks for 3 cycles (=
9 weeks) on day 1, 22 and 43. Oxaliplatin is given as a 2 h
intravenous infusion at a dose of 130 mg/m2 on day 1 followed
by capecitabine given orally at a dose of 1,000 mg/m2 twice
daily from the evening of day 1 to the morning of day 15
every 3 weeks.
Fluorouracil + Leucovorin + Oxaliplatin + Docetaxel
(FLOT) (4)
FLOT is administered in cycles of 2 weeks for 4 cycles (=
8 weeks) on day 1, 15, 29, and 43 pre- and postoperatively.
Docetaxel 50 mg/m2 is given as 1 h infusion, followed by
oxaliplatin 85 mg/m2 as a 2 h infusion, leucovorin 200 mg/m2
over 2 h, and 5-FU 2,600 mg/m2 as a 24 h-infusion, with oral
dexamethasone for prevention of fluid retention and allergic
reactions. It is recommended to give an equivalent of 8mg oral
dexamethasone BID for 3 days starting from the day before
docetaxel administration in the morning (8 a.m.) and evening
(8 p.m.) on the day before administration of docetaxel, together
with anti-emetic premedication on the day of chemotherapy and
to continue 1 or 2 days after to minimize undesirable effects
(Note: leucovorin may be replaced by sodium folinate according
to local standards).
Outcomes
Primary Endpoint
The primary endpoint in this study is Disease free survival (DFS).
This has been chosen because of the high proportion of high-
risk patients who progress within a short timeframe after surgery.
In the recent MRC ST03 trial which represents one of the most
contemporaneous use of perioperative chemotherapy the 1-year
DFS for node positive patients was only 60% with standard
postoperative chemotherapy (completion of the perioperative
concept) (28).
Secondary Endpoints
• Overall survival (OS).
• Pattern and rate of relapse.
• Rate of adverse events according to National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-
CTCAE v5.0).
• Global Health Status and Physical functioning according to
EORTC QLQ C30 including nutritional status assessment.
Other Pre-specified Endpoints
• Quality of life according to EORTC QLQ C30 (and 6
additional items).
• Correlation of patient reported outcomes, quality of life, and
nutritional status assessment with survival outcomes.
Screening Assessment
Participant timeline
Within 28 days
(4 weeks) prior
to randomization
Within 7 days
prior to
randomization
Within 1 day
prior to
randomization
Medical history X
Adverse event
assessment (CTCAE v5.0)
X
Physical examination 1 X
Performance status X
HBV, HCV, HIV serology X
Endocrine function2 X
12-lead ECG (in triplicate)
(2–5min apart)
X
LVEF (by MUGA or
ECHO), only if indicated
X
Disease assessment3 X
Surgery assessmentU X
Review of
prior/concomitant
medications
X
Quality of Life
questionnaire (QLQ-C30)
X
G8 screening for frailty for
patients older than 70
X
Hematology4 X(A)
Serum chemistry5 X(A)
Urine analysis X(A)
Pregnancy test6 X(B)
FFPE sample of biopsy X
FFPE sample of resection X
X. In all cases 1: Including BP, pulse, temperature, weight,
nutritional status.
2: Morning cortisol, ACTH, TSH (Free T3 and Free T4 in case of
abnormal TSH).
3: Disease assessment: Full chest/abdomen/pelvis (CT and/or
MRI); PET-CT scan may be an option.
UAssessment of the resection of the primary tumor. Type
of surgery and reconstruction performed (including if
splenectomy was performed); resection margins (R0, R1, R2);
Number of lymph nodes evaluated; Number of positive lymph
nodes; Lymph node stations dissected based on the operative
report; If applicable, type of the surgical complication
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graded according to the Clavien-Dindo Classification Version
2009 (29).
4: WBC, ANC, lymphocytes, eosinophils, basophils, RBC,
hemoglobin, hematocrit, platelets; coagulation parameters.
5: Albumin, ALP, AST, ALT, GGT, LDH, Amylase, Serum
phosphorous, Calcium total and ionized, Creatinine, Glucose,
Lipase, Magnesium total and ionized, Potassium, Sodium,
Total bilirubin, Uric acid; Calculated creatinine clearance;
Direct and indirect bilirubin as clinically indicated if total
bilirubin is ≥ 2xULN.
6: For pre-menopausal female subjects of childbearing
potential only.
A: To be repeated if more than 14 days prior to treatment start.
B: Pregnancy test to be repeated if more than 24 h from
treatment start.
Assessments During Treatment Period
First 3 months
after randomization
(Months 1–3 =
weeks 1–12)
Following 9 months
(Months 4–12 = weeks
13–48?)
Every 2 or
3 weeks
(+/– 5
days)
At 12
weeks (+/–
7 days)
Every 2
weeks
(+/– 5
days)
Every 12
weeks
(+/– 7
days)
Adverse event
assessment
(CTCAE v5.0)
Both arms X Both arms X IO arm
only X
Both arms
Disease
assessment by
imaging3
Both arms X Both arms
Physical
assessment
Both arms X Both arms X IO arm
only X
Both arms
Nutritional
assessment
Both arms X Both arms X IO arm only
Performance
status
Both arms X Both arms X IO arm
only X
Both arms
Quality of Life
Questionnaire
Both arms Both arms
12-lead ECG (in
triplicate) (2–5min
apart); LVEF (by
MUGA or ECHO)
Both arms, if clinically indicated
Concomitant
medications
Both arms X Both arms X IO arm
only X
Both arms
Hematology4 Both arms X Both arms X IO arm
only X
IO arm only
Serum chemistry5 Both arms X Both arms X IO arm
only X
IO arm only
Thyroid function
tests
IO Arm only,: every 6 weeks
Cortisol levels6 IO arm only, every 6 weeks
Pregnancy test7 Both arms, every 6 weeks IO arm only, every 6 weeks
Samples for
biobanking/TR
Both arms X
X. Mandatory.
1: Including BP, pulse, temperature, weight.
3: Disease assessment: Full chest/abdomen CT and/or MRI.
4: WBC, ANC, lymphocytes, eosinophils, basophils, RBC,
hemoglobin, hematocrit, platelets; coagulation parameters.
5: Albumin, ALP, AST, ALT, GGT, LDH, Amylase, Bicarbonate,
Calcium total and ionized, Chloride, Creatinine, Glucose,
Lipase, Magnesium total and ionized, Potassium, Sodium,
Total bilirubin, Uric acid; Calculated creatinine clearance;
Direct and indirect bilirubin as clinically indicated if total
bilirubin is ≥ 2xULN.
6: Only if clinically indicated.
7: For pre-menopausal female subjects of childbearing
potential only: urine or serum according to national
regulations/institution guidelines.
Assessment at End of Treatment for
Both Arms
Normal completion∗ Treatment discontinuation
Both arms Both arms
28 days after
last
treatment
dose
Due to
recurrence
Other
reasons
Adverse event
assessment (CTCAE
v5.0)
X X X
Clinical examination1 X X X
Hematology X X X
Serum chemistry X X X
Endocrine function
tests
IO arm only IO arm only IO arm only
12-L ECG X X X
Performance status X X X
Disease assessment by
imaging
X
Subsequent
anti-cancer therapy6
X X
Survival status X X X
Quality of life X according to
specified
timelines
X
Samples for biobanking
and TR
X According to
specified
timelines if
patient is fit
X=mandatory.
∗Control arm: completion of post-operative treatment
according to the 2016 ESMO guidelines.
Experimental arm: completion of 1 year post-operative
treatment with nivolumab 3 mg/kg IV Q2W plus ipilimumab
1 mg/kg IV Q6W for 1 year.
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Follow-up of Patients for Both Arms
Follow up during Year 2
Both arms
Follow-up during Year 3
to 5
Both arms
Every 3 months
(± 7 days)
Every 6 months
(± 14 days)
Adverse event
assessment (CTCAE v5.0)
X X
Clinical examination1 X X
WHO performance status X X
Disease assessment by
imaging
X X
Subsequent anti-cancer
therapy6
X X
Survival status X X
Quality of life X at month 15
Samples for biobanking
and TR
X
X. In all cases.
1: according to standard of care and institution guidelines.
6: Each patient will be followed until death or for ∼5 years
following enrollment in order to document the long-term
outcome (e.g., progression-free survival and overall survival).
Sample Size
The primary objective of the study is to detect an increase in DFS
with nivolumab plus ipilimumab given as adjuvant treatment. A
phase III trial design with an increased one-sided type I error of
0.1 will be used for this Phase II trial.
The estimate for the control group is a DFS rate at 1 year
of 65%. In ST03 (28), DFS rate at 1 year for node positive
patients was 68% with 95% CI: 62–73% (subgroup analysis). In
the MAGIC trial (7), in the 92 node positive patients who had
surgery and postoperative chemotherapy, DFS (from surgery)
rate at 1 year was 58% (95% CI: 47–67%).
The objective is to improve DFS rate at 1 year from 65 to
74% in the experimental arm. Assuming that DFS follows an
exponential distribution, this corresponds to HR = 0.7 and an
increase in median DFS from 19.3 to 27.6 months.
Using a one-sided log-rank test at a level of significance of
10%, a total of 142 events are required to reach 80% power.
Assuming an accrual rate at full speed (when all sites are
open) of 10 patients per month and taking into account the
opening of the sites, 2.52 patients/month are expected to be
randomized for months 1–3, 4.13 patients/month for months 4–
6, 5.80 patients/month for months 7–9, 7.56 patients/month for
months 10–12 and 10 patients/month thereafter.
Taking into account an overall dropout rate of 5% at 1 year,
we plan to randomize 240 patients in a 1:1 ratio between the
control arm and the experimental arm in order to observe
the required 142 events after an accrual period of 30 months
and an additional follow-up of 22 months after closing the
trial to patient entry. Total study duration is expected to
be 52 months.
The rate of events in the control arm will be closely monitored
during the trial to detect any departure from the assumption
early on.
DISCUSSION
The VESTIGE trial is, to the best of our knowledge, the
first to address switching adjuvant therapy in high risk
patients with resected esophageal and gastric cancer following
perioperative chemotherapy. It will offer patients the
opportunity to either continue with the current standard
of care (chemotherapy following surgery) or to be treated
with combination immunotherapy with nivolumab and low
dose ipilimumab. As the combination of nivolumab and
low dose ipilimumab has been associated with promising
response rates in patients with metastatic gastric and esophageal
cancer, we hypothesize that this novel approach will be
helpful in decreasing the risk of disease recurrence for high
risk patients.
Historically, high dose ipilimumab with nivolumab has
been associated with increased toxicity compared to nivolumab
alone. Emergent data suggest that low dose ipilimumab with
nivolumab has equivalent efficacy and reduced toxicity. For this
reason, patients in VESTIGE will be treated with nivolumab
and low dose ipilimumab. We also include the protocol
management algorithms for most common toxicities associated
with combination immunotherapy treatment.
Biomarkers associated with benefit from immunotherapy in
gastric and esophageal cancer are under study, amongst these,
PD-L1 immunohistochemistry and microsatellite instability are
the most well-validated. In VESTIGE, we will incorporate a
translational research programme including collection of pre-
treatment biopsies, post-chemotherapy resection specimens and
serial liquid biopsy on treatment to explore biomarkers predictive
of immune checkpoint blockade efficacy.
In conclusion, VESTIGE is an international phase II
randomized trial in high risk post resection gastric and
esophageal cancers post neoadjuvant chemotherapy. The aim
of the trial is to improve disease free survival by switching
from standard of care adjuvant chemotherapy to combination
immunotherapy with nivolumab and low dose ipilimumab.
The trial opened to recruitment in July 2019 and will enroll
240 patients over a 2 year period. For enquiries please
contact 1707@eortc.org.
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